Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Curie
About this trial
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient with suspicion of localised thymic epithelial tumour.
Age ≥ 18 years.
Treatment-naïve patient for this disease.
Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
Disqualifiers
Neoadjuvant chemotherapy.
No social security affiliation.
Person under legal protection.
Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
Trial design
Design model
Single group
Treatments tested in this trial
single arm for all patients
Other intervention* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery. * blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: single arm for all patientsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Somatic molecular characterisation of TETs
Description of genetic abnormalities in thymic tumours compared to non-tumourous thymic tissue (Whole Exome Sequencing RNA-sequencing technique, DNA Optical mapping);
Time frame
38 months2
Characterisation of the immune environment of TETs
Description of immune cells in the tumour environment, description of tumour infiltrating T cells
Time frame
38 months3
Molecular characterisation of TETs
Molecular constitutional characterisation of TETs with the technique of the Exome Sequencing (WES) on blood samples of patients with TETs
Time frame
38 monthsSecondary outcomes
1
Genomic characterisation of TETs
WES data analysis constitutional genetic alterations will be performed.
Time frame
38 months2
Characterisation of potential alterations in signalling pathways to identify potential therapeutic targets
Molecular analyses will be performed to identify potential alterations in signalling pathways that can be targeted by new therapies.
Time frame
38 months3
Identification of potential neoepitopes
Analysis of TETs single-cell RNA-seq data will be performed.
Time frame
38 months4
Transcriptomic characterisation of TETs
Transcriptome sequencing analysis will be performed.
Time frame
38 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov